Table 3:
Univariate analysis for OS, RFS, NRM, and relapse
| OS | RFS | NRM | Relapse | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | #evt/n | HR(95 %CI) | p-value | #evt | HR(95 %CI) | p-value | #evt | SDHR(95 %CI) | p-value | #evt | SDHR(95 %CI) | p-value |
| Age at BMT | ||||||||||||
| ≤ 60 | 4/16 | 7 | 1 | 6 | ||||||||
| > 60 | 12/2 6 | 2.58(0.83–8.04) | 0.10 | 15 | 1.60(0.65–3.99) | 0.31 | 11 | 9.46(1.37–65.16) | 0.02 | 4 | 0.26(0.08–0.80) | 0.02 |
| Age increase per decade | 16/42 | 1.31 (0.67–2.55) | 0.43 | 22 | 1.20 (0.68–2.14) | 0.53 | 12 | 3.18 (1.05–9.62) | 0.04 | 10 | 0.48 (0.28–0.82) | 0.007 |
| Gender | ||||||||||||
| Male | 10/25 | 14 | 6 | 8 | ||||||||
| Female | 6/17 | 0.98(0.35–2.69) | 0.97 | 8 | 0.95(0.40–2.26) | 0.90 | 6 | 1.55(0.52–4.68) | 0.43 | 2 | 0.37(0.08–1.58) | 0.18 |
| BMT Year | ||||||||||||
| 2010–2016 | 5/14 | 10 | 4 | 6 | ||||||||
| 2017–2020 | 11/28 | 1.36 (0.46–4.05) | 0.56 | 12 | 0.78(0.33–1.83) | 0.57 | 8 | 0.98(0.30–3.18) | 0.97 | 4 | 0.48(0.16–1.47) | 0.20 |
| Years from myelofibrosi s to BMT | 16/42 | 1.01(0.94–10.9) | 0.70 | 22 | 1(0.94–1.07) | 0.96 | 12 | 0.99(0.87–1.13) | 0.92 | 10 | 1.02(0.95–1.09) | 0.62 |
| HCT-CI | ||||||||||||
| 0–1 | 7/20 | 11 | 6 | 5 | ||||||||
| ≥ 2 | 9/22 | 1.30(0.48–3.50) | 0.60 | 11 | 1.14(0.49–2.65) | 0.76 | 6 | 0.96(0.32–2.87) | 0.94 | 5 | 1.23(0.36–4.22) | 0.74 |
| Diagnosis | ||||||||||||
| Primary myelofi brosis | 6/19 | 8 | 5 | 3 | ||||||||
| Post ET/PV | 10/23 | 1.57(0.57–4.33) | 0.38 | 14 | 1.85(0.75–4.34) | 0.19 | 7 | 1.31(0.43–3.98) | 0.63 | 7 | 2.23(0.62–0.81) | 0.22 |
| Prior JAK inhibitor use | ||||||||||||
| No | 1/8 | 2 | 1 | 1 | ||||||||
| Yes | 15/34 | 4.69(0.61–36.18) | 0.14 | 20 | 3.87(0.88–16.98) | 0.07 | 11 | 2.70(0.31–23.48) | 0.37 | 9 | 3.01(0.35–26.10) | 0.32 |
| DIPSS-Plus at BMT | ||||||||||||
| Intermediate 1/2 risk | 12/33 | 16 | 9 | 7 | ||||||||
| High risk | 4/9 | 1.25(0.40–3.90) | 0.70 | 6 | 1.29(0.51–3.31) | 0.59 | 3 | 1.25(0.35–4.45) | 0.73 | 3 | 1.36(0.43–4.25) | 0.60 |
| MIPSS70 v2.0 at BMT | ||||||||||||
| Low/Intermediate | 4/10 | 5 | 2 | 3 | ||||||||
| High/Very high | 12/32 | 1.10(0.35–3.42) | 0.87 | 17 | 1.36(0.50–3.71) | 0.54 | 10 | 1.76(0.40–7.83) | 0.46 | 7 | 0.84(0.22–3.15) | 0.79 |
| Spleen size | ||||||||||||
| at BMT | ||||||||||||
| 11–17cm | 4/18 | 4 | 4 | 0 | ||||||||
| >17cm/Prior splenect omy | 12/24 | 2.24(0.72–6.96) | 0.16 | 18 | 3.5(1.18–10.37) | 0.02 | 8 | 1.56(0.49–4.99) | 0.46 | 10 | – | 0.01 |
| Driver mutation | ||||||||||||
| JAK2 | 10/26 | 13 | 9 | 4 | ||||||||
| CALR | 4/9 | 0.91(0.28–2.91) | 0.87 | 6 | 1.28(0.48–3.43) | 0.62 | 1 | 0.28(0.03–2.38) | 0.24 | 5 | 5.41(1.68–17.47) | 0.00 5 |
| MPL/ Triple negative | 2/7 | 0.62(0.13–2.85) | 0.54 | 3 | 0.74(0.21–2.61) | 0.64 | 2 | 0.78(0.17–3.64) | 0.76 | 1 | 0.85(0.09–7.92) | 0.88 |
| High-risk cytogenetics | ||||||||||||
| No | 16/35 | 20 | 12 | 8 | ||||||||
| Yes | 0/7 | Not evaluable | 2 | 0.33(0.08–1.41) | 0.14 | 0 | Not evaluable | 2 | 1.21(0.29–5) | 0.80 | ||
| High-risk somatic mutations | ||||||||||||
| No | 5/17 | 9 | 4 | 5 | ||||||||
| Yes | 11/25 | 1.81(0.63–5.24) | 0.27 | 13 | 1.42(0.60–3.36) | 0.43 | 8 | 1.52(0.47–4.92) | 0.49 | 5 | 0.93(0.29–3.02) | 0.90 |
| ASXL1 | ||||||||||||
| Absent | 6/22 | 11 | 5 | 6 | ||||||||
| Present | 10/20 | 2.36(0.85–6.6) | 0.09 | 11 | 1.85(0.77–4.43) | 0.17 | 7 | 1.73(0.57–5.3) | 0.34 | 4 | 1.09(0.32–3.7) | 0.89 |
| Number of high-risk mutations | ||||||||||||
| 0 | 5/17 | 9 | 4 | 5 | ||||||||
| 1 | 5/9 | 2.16(0.62–7.52) | 0.23 | 6 | 1.5(0.53–4.21) | 0.45 | 4 | 2.07(0.55–7.79) | 0.28 | 2 | 0.73(0.14–3.7) | 0.70 |
| >=2 | 6/16 | 1.6(0.48–5.26) | 0.44 | 7 | 1.35(0.49–3.72) | 0.56 | 4 | 1.20(0.31–4.69) | 0.79 | 3 | 1.14(0.3–4.41) | 0.85 |
| Donor platform | ||||||||||||
| Haploidentical family | 13/33 | 19 | 10 | 9 | ||||||||
| MRD/MUD | 2/6 | 0.63(0.14–2.78) | 0.54 | 2 | 0.39(0.09–1.69) | 0.21 | 1 | 0.44(0.07–2.86) | 0.39 | 1 | 0.50(0.06–4.41) | 0.53 |
| MMUD | 1/3 | 0.62(0.08–4.78) | 0.65 | 1 | 0.41(0.05–3.04) | 0.38 | 1 | 0.86(0.16–4.60) | 0.86 | 0 | 0(0–0) | – |
| Graft source | ||||||||||||
| Bone marrow | 2/7 | 5 | 1 | 4 | ||||||||
| PB | 14/35 | 2.06(0.46–9.31) | 0.35 | 17 | 0.92(0.34–2.50) | 0.86 | 11 | 2.54(0.40–16.29) | 0.33 | 6 | 0.34(0.11–0.99) | 0.05 |
| TBI | ||||||||||||
| 200 cGy | 6/19 | 12 | 5 | 7 | ||||||||
| 400 cGy | 10/23 | 2.22(0.72–6.85) | 0.17 | 10 | 1.46(0.57–3.78) | 0.43 | 7 | 1.24(0.41–3.76) | 0.71 | 3 | 0.78(0.24–2.53) | 0.68 |
(BMT, blood or marrow transplantation; DIPSS, dynamic international prognostic scoring system; #evt, number of events; MIPSS, Mutation Enhanced International Prognostic Scoring System; MRD, matched related donor; MUD, matched unrelated donor; n, number of patients; NRM, non-relapse mortality; OS, overall survival; PB, peripheral blood; RFS, relapse free survival; TBI, total body irradiation)